Indiana Code 25-1-22-13. Prohibition on providing gender transition procedures to a minor; prohibition on aiding or abetting; exclusions; prescribing
(b) Except as provided in subsection (c), a physician or other practitioner may not aid or abet another physician or practitioner in the provision of gender transition procedures to a minor.
Terms Used In Indiana Code 25-1-22-13
- gender: means the psychological, behavioral, social, and cultural aspects of being male or female. See Indiana Code 25-1-22-1
- gender transition: means the process in which an individual shifts from identifying with and living as a gender that corresponds to his or her sex to identifying with and living as a gender different from his or her sex, and may involve social, legal, or physical changes. See Indiana Code 25-1-22-3
- gender transition hormone therapy: means :
Indiana Code 25-1-22-4
- gender transition procedures: means any medical or surgical service, including physician's services, practitioner's services, inpatient and outpatient hospital services, or prescribed drugs related to gender transition, that seeks to:
Indiana Code 25-1-22-5
- minor: means an individual who is less than eighteen (18) years of age. See Indiana Code 25-1-22-7
- physician: means an individual who is licensed under Indiana Code 25-1-22-9
- practitioner: means an individual who provides health services and holds:
Indiana Code 25-1-22-10
- sex: means the biological state of being male or female, based on the individual's sex organs, chromosomes, and endogenous hormone profiles. See Indiana Code 25-1-22-12
(1) Services to individuals born with a medically verifiable disorder of sex development, including an individual with external biological sex characteristics that are irresolvably ambiguous, including individuals born with forty-six (46) XX chromosomes with virilization, born with forty-six (46) XY chromosomes with undervirilization, or having both ovarian and testicular tissue.
(2) Services provided when a physician or practitioner has diagnosed a disorder of sexual development that the physician or practitioner has determined through genetic or biochemical testing that the individual does not have normal sex chromosome structure, sex steroid hormone production, or sex steroid hormone action.
(3) The treatment of any infection, injury, disease, or disorder that has been caused by or exacerbated by the performance of gender transition procedures.
(4) Any medical or surgical service undertaken because the individual suffers from a physical disorder, physical injury, or physical illness that would, as certified by a physician or practitioner, place the individual in imminent danger of death or impairment of major bodily function unless the medical or surgical service is performed.
(d) A physician or practitioner within the practitioner’s scope of practice may continue to prescribe to an individual, who was taking a gender transition hormone therapy on June 30, 2023, as part of a gender transition procedure, gender transition hormone therapy until December 31, 2023. This subsection expires January 1, 2024.
As added by P.L.10-2023, SEC.1.